The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia

British Journal of Haematology

Volumn 149, Issue 3, 2010, Pages 383-387

  Del Poeta, Giovanni ^a   Ammatuna, Emanuele ^a,b   Lavorgna, Serena ^a,b   Capelli, Giovanni ^c   Zaza, Serena ^a,b   Luciano, Fabrizio ^a   Ottone, Tiziana ^a,b   Del Principe, Maria Ilaria ^a   Buccisano, Francesco ^a   Maurillo, Luca ^a   Panetta, Paola ^a,b   De Fabritiis, Paolo ^a   Stasi, Roberto ^d   Venditti, Adriano ^a   Amadori, Sergio ^a   Lo Coco, Francesco ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Bax bcl 2; FLT3 ITD; Nucleophosmin gene; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; NUCLEOPHOSMIN; PROTEIN BAX; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE DUPLICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BCL-2-ASSOCIATED X PROTEIN; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; TUMOR MARKERS, BIOLOGICAL;

EID: 77950799067     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08098.x     Document Type: Article

References (15)

1. Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.P., Muus, P., Lefrère, F., Berneman, Z., Fillet, G., Denzlinger, C., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F., De Witte, T. EORTC/GIMEMA Leukemia Group (2005) Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomised phase 3 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC/GIMEMA) Leukemia Groups. Blood, 106, 27 34.
2. Chan, P.K. Chan, F.Y. (1999) A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin. Biochemical Pharmacology, 57, 1265 1273.
3. Del Poeta, G., Venditti, A., Del Principe, M.I., Maurillo, L., Buccisano, F., Tamburini, A., Cox, M.C., Franchi, A., Bruno, A., Mazzone, C., Panetta, P., Suppo, G., Masi, M. Amadori, S. (2003) Amount of spontaneous apoptosis detected by bax/bcl-2 ratio predicts outcome in acute myeloid leukemia. Blood, 101, 2125 2131.
4. Döhner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rücker, F.G., Corbagioglu, A., Bullinger, L., Fröhling, S. Döhner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740 3746.
5. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G., Martelli, M.F. GIMEMA Acute Leukemia Working Party. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. New England Journal of Medicine, 352, 254 266. (Pubitemid 40110814)
6. Falini, B., Nicoletti, I., Martelli, M.F. Mecucci, C. (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood, 109, 874 885.
7. Gale, R.E., Green, C., Allen, C., Mead, A.J., Burnett, A.K., Hills, R.K., Linch, D.C. Medical Research Council Adult Leukaemia Working Party. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776 2784.
8. Kerr, L.E., Birse-Archbold, J.L., Short, D.M., McGregor, A.L., Heron, I., Macdonald, D.C., Thompson, J., Carlson, G.J., Kelly, J.S., McCulloch, J. Sharkey, J. (2007) Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene, 26, 2554 2662.
9. Noguera, N.I., Ammatuna, E., Zangrilli, D., Lavorgna, S., Divona, M., Buccisano, F., Amadori, S., Mecucci, C., Falini, B. Lo-Coco, F. (2005) Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia, 19, 1479 1482.
10. Samuels, B.L., La.rson, R.A., Le Beau, M.M., Daly, K.M., Bitter, M.A., Vardiman, J.W., Barker, C.M., Rowley, J.D. Golomb, H.M. (1988) Specific chromosome abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vitro. Leukemia, 2, 79 83.
11. Schlenk, R.F., Döhner K, Krauter.J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., Döhner, H. German-Austrian Acute Myeloid Leukemia Study Group. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909 1918.
12. Schlenk, R.F., Dohner, K., Kneba, M., Götze, K., Hartmann, F., Del Valle, F., Kirchen, H., Koller, E., Fischer, J.T., Bullinger, L., Habdank, M., Späth, D., Groner, S., Krebs, B., Kayser, S., Corbagioglu, A., Anhalt, A., Benner, A., Fröhling, S., Döhner, H. German-Austrian AML Study Group (AMLSG). (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica, 94, 54 60.
13. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733 3739.
14. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011 4020.
15. Vignetti, M., De Witte, T.M., Suciu, S., Zittoun, R., Resegotti, L., Liso, V., Willemze, R., Belhabri, A., Amadori, S., Giustoli, R., Labar, R., Fioritoni, G., Rossi-Ferrini, P., Leoni, G., Jehn, U., Fazi, P., Petti, M.C. Mandelli, F. (2003) Daunorubicin (DNR) vs mitoxantrone (MTZ) vs idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem cell transplantation (SCT): results of the EORTC-GIMEMA. Blood, 102, 175a.